Category: Partners

AUSTIN, TX / ACCESS Newswire / May 28, 2025 / Volcon ePowersports (Nasdaq:VLCN) (“Volcon” or the “Company”), the first all-electric, off-road powersports company, is pleased to announce the launch of a new floor plan financing and retail financing program provided by Dealer Direct Financial, a department of First Community Bank. This initiative will enable Volcon’s network of dealers to finance their inventory purchases, providing them with enhanced access to the Company’s groundbreaking electric off-road vehicles.

The floor plan will provide flexible financial solutions designed to support inventory acquisition and drive sales of Volcon’s cutting-edge products. By facilitating dealer access to affordable financing, Volcon aims to expand its market presence and ensure that customers nationwide can experience the next generation of off-road adventure with the Company’s electric vehicles.

“We are excited to offer this floor plan program to our dealer network, which will empower them to grow their businesses while helping accelerate the adoption of our all-electric off-road vehicles,” said John Kim, CEO of Volcon. “This program reflects our commitment to strengthening dealer relationships and furthering our mission to revolutionize the powersports industry with sustainable, high-performance electric vehicles.”

The new floor plan program is a significant step in Volcon’s strategy to scale its operations and support its growing network of dealers as they meet increasing demand for Volcon’s innovative electric powersports offerings.

“We’re proud to partner with Volcon in supporting their innovative approach to the powersports market,” said Steve Wilcoxon, president of Dealer Direct Financial. “Our floor plan program is designed to give dealers the flexibility and access they need to meet customer demand and grow their businesses. By offering tailored financing solutions, we’re helping bring Volcon’s electric off-road vehicles to more showrooms-and more riders-across the country.”

About Volcon

Based in the Austin, Texas area, Volcon was founded as the first all-electric power sports company producing high-quality and sustainable electric vehicles for the outdoor community. Volcon electric vehicles are the future of off-roading, not only because of their environmental benefits but also because of their near-silent operation, which allows for a more immersive outdoor experience.

Volcon’s vehicle roadmap includes both motorcycles and UTVs. Its first product, the innovative Grunt, began shipping to customers in late 2021 and combines a fat-tired physique with high-torque electric power and a near-silent drive train. The Volcon Grunt EVO, an evolution of the original Grunt with a belt drive, an improved suspension, and seat, began shipping to customers in October 2023. The Brat is Volcon’s first foray into the wildly popular eBike market for both on-road and off-road riding and is currently being delivered to dealers across North America. In 2024, Volcon entered the rapidly expanding LUV and UTV market and shipped its first production MN1 unit in October 2024. The new MN1 and HF1 products empower the driver to explore the outdoors in a new and unique way that gas-powered units cannot. They offer the same thrilling performance of a standard LUV / UTV without the noise (or pollution), allowing the driver to explore the outdoors with all their senses.

Volcon Contacts

For Media: media@volcon.com
For Dealers: dealers@volcon.com
For Investors: investors@volcon.com
For Marketing: marketing@volcon.com

For more information on Volcon or to learn more about its complete eBike, motorcycle and side-by-side line-up, visit: www.volcon.com

For more information about First Community Bank’s Dealer Direct program, call 870-376-7123 or visit https://dealerdirectfinancial.com.

Forward-Looking Statements

Some of the statements in this release referenced in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, whether floor plan program will increase dealer purchases of Volcon products. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC’s website, www.sec.gov.

About Dealer Direct Financial

Dealer Direct Financial is a department of First Community Bank, headquartered in Batesville, Arkansas. The program was established in 2005 in response to a need among local manufacturers for floor plan and retail financing solutions. Since its inception, Dealer Direct Financial has experienced significant growth and now services thousands of dealers nationwide. The program offers specialized financing for manufacturers, including floor plans and retail installment loans for tractors (up to 75hp), trailers, boats, powersports, motorcycles, lawn equipment, and farm equipment.

About First Community Bank

First Community Bank, which is locally owned and managed, opened August 4, 1997, in Batesville, Arkansas, and currently operates in 34 locations across Arkansas and Missouri. First Community Bank employs 600 professional bankers, and reports assets of $3.09 billion as of March 31, 2025.

SOURCE: Volcon, Inc.

View the original press release on ACCESS Newswire

TAMPA, FLORIDA / ACCESS Newswire / May 28, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare infrastructure company transforming the prescription drug ecosystem, today announced key additions to its executive leadership team and Board of Directors. These strategic appointments reflect the Company’s commitment to executing on its growth strategy, enhancing operational scale, and delivering long-term shareholder value.

Key Leadership Appointments

Wellgistics has appointed a diverse and deeply experienced group of executives to drive execution across the Company’s operations:

Tony Madsen, Chief Operating Officer (COO) – A seasoned executive with over a decade of regulatory compliance, cybersecurity, and healthcare operations scaling experience. Mr. Madsen will oversee execution across Wellgistics’ platform and ensure cross-functional alignment and operational excellence. Since 2020, he served as Managing Partner at Nomad Capital, an investment firm dedicated to reshaping capital structures and fine-tuning operational efficiencies. For the six years prior, he was Director of Cybersecurity at Cingo Solutions, an SOC2-certified managed detection and response cybersecurity provider. He holds a degree in Economics from Brigham State University.

Shelley Bailey, Chief Revenue Officer (CRO) – A proven growth strategist, Ms. Bailey brings deep industry knowledge and leadership in scaling healthcare sales teams and revenue operations across multiple verticals. Most recently, she served as Chief Strategy Officer at Wellgistics, where she combined her specialty pharmacy, government affairs, and supply chain experience to create tailored employer solutions. For the three years prior, she was the Chair of the Oregon Prescription Drug Affordability Board, a branch of that state’s largest consumer protection and business regulatory​ agency. Between 2020 and 2025 she served as founder and CEO of Famlee Health, which provided clinical assessment, diagnosis and step-therapy treatment for fertility from home. For the seven years prior, Ms. Bailey was a Specialty Pharmacy Consultant to legislators, pharmaceutical, and healthcare companies with a focus on specialty pharmacy and 340B programs. Between 2000 and 2017 she was CEO and co-owner of Central Drugs Specialty Pharmacy in Oregon. She earned an MBA from Babson F.W. Olin Graduate School of Business.

Srini Kalla, Chief Information Officer (CIO) – Mr. Kalla will lead the modernization of Wellgistics’ digital and data infrastructure, driving the Company’s AI integration strategy, compliance frameworks, and platform interoperability. Prior to joining Wellgistics, he worked with Optum Workers’ Comp and Auto No-Fault, a Minnesota-based insurance company, where he first served as Executive Director and then Vice President IT. Previously, he was employed in Analyst-Security Operations and Specialist-Operations Support by Verizon Data Services. He holds MS and MIS degrees from the University of Florida.

Vasudev Patel, Product Owner – Mr. Patel will spearhead product development across the Company’s AI-driven prescription routing tools, pharmacy technology platforms, and digital patient engagement solutions. Prior to joining Wellgistics, Mr. Patel held the position of Agile Product Owner with Evernorth Health Services. From 2012 to 2022 he served as Senior Business Analyst at UnitedHealth Group. He previously held Business Analyst positions with both Express Scripts and Merrill Lynch/Bank of America. He holds an MBA, Finance, from Brain Wells University in London.

Ari Aichbhaumik, Senior Vice President of Supply Chain – Mr. Aichbhaumik brings a strong track record of optimizing pharmaceutical supply chain networks at scale, with expertise in distribution, logistics, and global procurement. Before joining Wellgistics, Ari held a number of pharmacy operations management positions including Senior Vice President with Bayvrio, VP, Pharmacy Practice and Specialty Solution at Eversana, and Director of Pharmacy Operations at WellDyne, Inc. He holds degrees in Pharmacy from Temple University and Pharmaceutical Economics from University of Florida, as well as an MS, Computer Information and Business Management from the University of Phoenix.

Kim Dresser, Director of Human Resources – Ms. Dresser will drive talent acquisition, culture transformation, and HR infrastructure as Wellgistics continues to scale nationally.

Most recently, Kim served as Human Resources Director for Leonard Buildings & Truck Accessories, a 150-store, 18-state manufacturer and distributor. Previously, she was Human Resources Manager for MVP Group International, one of the world’s largest manufacturers of private label scented candles. From 2016 through 2021 she served as Production Manager at World Wide Protective Products, a maker of custom hand and body protection products. She holds an Associate degree in Business Management from Surry Community college in North Carolina.

Board Appointment

Michael Peterson, Member, Board of Directors – A veteran public company executive and capital markets strategist bringing significant governance and financial experience, Mr. Peterson will help guide Wellgistics’ strategic expansion and shareholder engagement.

Since 2022 Michael has served as CEO, Director, and Founder of Lafayette Energy, a Utah based oil and gas exploration company. He also presently serves as Director with both the biopharma company, Ocean Biomedical, and with the energy exploration company, Indonesia Energy Corporation. Michael also served as Director and CEO with Trio Petroleum Corp and as Director with TRxADE Health, Inc. (Nasdaq: MEDS), a wholesale drug selling platform. He holds an MBA, Finance, from Brigham Young University Mariott School of Business.

“This is more than just leadership expansion-it’s the strategic assembly of a world-class team capable of executing on our national vision to fundamentally shift the way prescription drugs move across the supply chain in America,” commented Brian Norton, CEO of Wellgistics Health. “We’re not just optimizing logistics-we’re rebuilding the infrastructure of healthcare medicine delivery to create lasting value for employer groups, patients, pharmacies, and the entire healthcare ecosystem.”

About Wellgistics Health

Wellgistics Health, Inc. is a publicly traded healthcare infrastructure company redefining how medications move, are priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a nationwide network of over 6,000 independent pharmacies.

Wellgistics Health provides real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment solutions, while equipping pharmacies with integrated financial, clinical, and digital tools. Its end-to-end platform supports a broad range of therapeutic areas from specialty-lite to chronic maintenance medications by eliminating friction, accelerating reimbursements, and enabling direct, transparent connections between manufacturers, providers, pharmacies, and patients.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health’s statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans, including without limitation its plan in connection with certain financings and cryptocurrencies and outlook and actions with respect to incurring future expenses. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health’s filings with the SEC, which are available for review at www.sec.gov.

For more information, please contact:

Media Contact: media@wellgisticshealth.com
Investor Relations: investors@wellgisticshealth.com

Investor Relations Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

Made in the USA, Built to Perform: Ultra-High Molecular Weight Polyethylene Parts Designed for Durability, Customization, and Speed

SIOUX FALLS, SD / ACCESS Newswire / May 28, 2025 / Global Polymer Industries, a premier compression molder of Ultra-High Molecular Weight Polyethylene (UHMW-PE), is proud to announce its continued leadership as North America’s top provider of custom-molded UHMW-PE components. From forestry and food processing to wastewater, agriculture, and advanced OEM manufacturing, Global Polymer delivers high-performance net-shape parts engineered to outperform traditional materials in even the harshest environments.

UHMW-PE is a unique thermoplastic with a molecular weight between 3.1 and 10 million, resulting in exceptional wear resistance, impact strength, low friction, and chemical resistance. But what sets Global Polymer Industries apart is not just the material, it’s how they mold it.

“Our compression-molding capabilities allow us to produce net- or near-net-shape UHMW-PE components that eliminate the need for costly secondary machining,” said Jeff Hieb, Plant Manager for Global Polymer. “That means faster turnaround, lower overhead, and exact-fit parts tailored to each customer’s equipment needs.”

Built in America. Built for Reliability.
With U.S.-based operations, Global Polymer helps manufacturing companies and OEMs reduce reliance on overseas suppliers and achieve shorter lead times. By partnering with Global Polymer, companies gain a competitive edge:

• Superior Material Performance – UHMW-PE parts resist wear, abrasion, moisture, and chemicals better than many metals or standard plastics.

• Faster Delivery – Located in South Dakota, Global Polymer can produce and ship custom parts in significantly less time than offshore competitors.

• Custom Molding Expertise – Whether it’s sprockets for agriculture, wear liners for conveyors, or bushings for car wash systems, Global Polymer builds each part to spec and scale.

Why OEMs Are Switching to UHMW-PE from Global Polymer
Many OEM engineers are discovering that UHMW-PE’s properties, combined with Global Polymer’s net-shape molding process, can replace more expensive, heavier, or high-maintenance materials like steel, rubber, or nylon.

Industries seeing the most benefit include:

• Forestry: Custom bushings, sprockets, and log-handling components that last longer with less maintenance.

• Water & Wastewater: Chemical- and abrasion-resistant parts like liners, seals, and auger bearings.

• Distribution & Packaging: Wear strips, chain guides, and dock bumpers that enhance flow and reduce friction.

• Transportation & Marine: Corrosion-resistant snowplow blades and dock protectors that perform in rugged environments.

• OEM Manufacturing: Custom-molded, high-volume parts, like wear pads, chain guides, and bushings, delivered with consistency and precision.

Global Polymer’s facility is engineered for both large-scale production and specialty part runs. From high-volume replacement parts to custom components for new equipment, their team partners directly with procurement specialists, engineers, and supply chain managers to streamline sourcing and maximize ROI.

About Global Polymer
Global Polymer is a North American leader in the compression molding of UHMW-PE components. With advanced manufacturing capabilities and an unwavering commitment to quality, the company specializes in custom-molded net-shape parts used across a wide range of industries. Built in the USA, Global Polymer helps OEMs reduce costs, improve part performance, and accelerate delivery-without compromising durability or precision.

Media Contact:
Global Polymer
Phone: (605) 256-3150
Website: www.globalpolymer.com
Email: Emily Sorenson – emilys@henkinschultz.com

SOURCE: Global Polymer Industries

View the original press release on ACCESS Newswire

TORONTO, ON AND BREDA, THE NETHERLANDS / ACCESS Newswire / May 28, 2025 / Organto Foods Inc. (TSXV:OGO)(OTC PINK:OGOFF)(FSE:OGF) (“Organto” or “the Company”), is pleased to announce its financial results for the three months ended March 31, 2025. All amounts are expressed in Canadian dollars and in accordance with International Financial Reporting Standards (IFRS), except where specifically noted.

Hi-Lites

• Sales of $13.6 million, an increase of 193.5% versus the prior year. Largest quarterly sales in the history of the Company and representing 66% of total fiscal 2024 sales.

• Gross profit of $1.1 million, an increase of 298.1% versus the prior year. Largest quarterly gross profit dollars in the history of the Company.

• Cash operating expenses of 6.8% of sales versus 10.5% in the prior year. Lowest cash operating expenses as a percentage of sales in the history of the Company.

• Income from operations of $0.1 million versus a loss of $0.3 million in the prior year.

• EBITDA⁽¹⁾ (Earnings before interest, taxes, depreciation and amortization) of $0.3 million, the first positive EBITDA quarter in the history of the Company.

“We’re very pleased with our first-quarter 2025 results, which we believe are a powerful reflection of the strong momentum building in our business. These results are the direct outcome of the extensive restructuring and strategic realignment we’ve executed over the past 18 months, laying a solid foundation for sustained growth, stability, and a clear path to profitability.

As our results reflect, we have made substantial progress: we’ve streamlined our product portfolio, re-energized our go-to-market strategies, and significantly reduced operating costs. The first quarter of 2025 delivered exceptional sales and margin growth, all on a leaner, more efficient cost base, resulting in our first-ever positive EBITDA quarter. With strong, ongoing momentum and a continued focus on achieving positive cash flow, we’re moving forward with confidence. Our recent successful private placement, shares-for-debt settlements, and the imminent conversion of our convertible debentures into equity only amplify our excitement about what’s ahead. We’re passionately committed to building a world-class company serving the fast-growing healthy foods market, and in doing so creating lasting value for our partners, customers, team, and shareholders”, commented Steve Bromley, Chair and Chief Executive Officer.

Fiscal 2025 First Quarter Results Overview

• Sales of $13.6 million versus $4.6 million in the prior year, an increase of approximately 194%. Sales grew as new customers were added, while a number of existing customers increased their purchases. Q-1 sales represent the largest quarterly sales in the history of the Company and 66% of total fiscal 2024 sales.

• Gross profit of $1.1 million or 8.2% of sales, versus $0.3 million or 6.0% of sales in the prior year, an increase of approximately 298% in gross profit dollars. Adjusted gross profit⁽¹⁾ was $1.1 million or 8.3% of sales when accounting for the impact of realized gains on derivatives, versus $0.2 million or 4.7% of sales in the prior year.

• Cash operating expenses of $0.9 million or 6.8% of sales versus $0.5 million or 10.5% of sales in the prior year. Operating expenses have stabilized following the sales of three subsidiaries in Q-2 2024 and reflect the increased costs of operating that were previously borne by the sold subsidiaries. First quarter costs include approximately $20,000 in legal and listing fees related to re-listing activities.

• Income from operations of $0.1 million versus a loss of $0.3 million in the prior year. Adjusted income from operations of $0.2 million in the first quarter, when adjusted for costs associated with re-listing and realized gains on derivatives.

• Net loss for the period of $0.3 million after accounting for interest and accretion costs of $0.3 million and unrealized losses on derivative assets and liabilities of $0.2 million, versus a loss in the prior year of $1.5 million which includes discontinued operations.

• EBITDA⁽¹⁾ of $0.3 million versus a loss in the prior year of $1.2 million

The Company’s filings, including Audited Financial Statements and accompanying Management’s Discussion and Analysis for the year ended December 31, 2024 at www.SEDARplus.ca or at the Company’s website at www.organto.com under the Investors tab.

Grant of Stock Options

The Company has also granted stock options (the “Options”) exercisable to acquire up to 1,400,000 common shares to directors, officers and employees of the Company at a price of $0.35 per common share, expiring on May 27, 2030. 775,000 of the Options granted will vest 25% immediately and 25% every six months thereafter; and 625,000 of the Options granted will vest 20% immediately and 20% on each anniversary thereafter.

The Options were granted pursuant to the Company’s stock option plan which was last approved by shareholders at the Annual Meeting of Shareholders on March 12, 2025.

ON BEHALF OF THE BOARD,

Steve Bromley
Chair and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For more information contact:
Investor Relations
info@organto.com
John Rathwell, Senior Vice President, Corporate Development and Investor Relations
647 629 0018

1. The information presented herein refers to the non-IFRS financial measures of adjusted gross profit and EBITDA. We hedge currencies for certain product categories where either the supply or sales commitments are fixed in foreign currencies. The gains and losses from these hedging activities are combined with gross profit to determine adjusted gross profit. We also refer to EBITDA, which is Earnings before interest, taxes, depreciation and amortization. These two measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS. Non-IFRS financial measures should not be considered in isolation nor as a substitute for analysis of the Company’s financial information reported under IFRS and are unlikely to be comparable to similar measures presented by other issuers. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company’s results of operations from management’s perspective and thus highlight trends in its business that may not otherwise be apparent when relying solely on IFRS measures. The Company believes that securities analysts, investors and other interested parties frequently use non-IFRS financial measures in the evaluation of the Company. The Company’s management also uses non-IFRS financial measures to facilitate operating performance comparisons from period to period and to prepare annual operating budgets and forecasts.

ABOUT ORGANTO

Organto is an integrated provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-light business model to serve a growing socially responsible and health-conscious consumer around the globe. Organto’s business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders.

FORWARD LOOKING STATEMENTS

This news release may include certain forward-looking information and statements, as defined by law including without limitation Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting Organto’s business model and markets; Organto’s belief that the Company has made solid progress in the restructuring and realignment of its business focused on a clear path to profitability, sustained growth and long-term stability; Organto’s belief that the impact of these restructuring efforts is a key driver of its first quarter results; Organto’s belief that the combination of financing and debt restructuring efforts combined with strong sales and margin growth on a streamlined cost base positions the Company for an exciting future; Organto’s belief that it remains focused on building a world class company focused on growing healthy foods markets with the gaol of building shareholder value; management’s beliefs, assumptions and expectations; and general business and economic conditions. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including without limitation assumptions about the following: the ability and time frame within which Organto’s business model will be implemented and product supply will be increased; cost increases; dependence on suppliers, partners, and contractual counter-parties; changes in the business or prospects of Organto; unforeseen circumstances; risks associated with the organic produce business generally, including inclement weather, unfavorable growing conditions, low crop yields, variations in crop quality, spoilage, import and export laws, and similar risks; transportation costs and risks; general business and economic conditions; and ongoing relations with distributors, customers, employees, suppliers, consultants, contractors, and partners. The foregoing list is not exhaustive and Organto undertakes no obligation to update any of the foregoing except as required by law.

SOURCE: Organto Foods, Inc.

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA.

Event Information:

Event	NanoViricides Presentation at the BIO International Convention, 2025, Boston, MA
Day & Date	Monday, June 16, 2025
Time	2:30 pm
Location	Room 153B, Boston Convention and Exhibition Center

Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.

Dr. Diwan will also be available for meetings in the BIO Partnering™ match-making platform during the Convention from June 16th through June 19th, 2025.

NanoViricides’ Current Antiviral Drugs Pipeline

NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region.

NV-387 is a revolutionary broad-spectrum drug candidate designed to mimic host-side features that the virus particle uses as the first landing site in order to mount a cellular infection. An estimated 90-95% of human pathogens utilize the same common landing feature that is mimicked by NV-387, giving the drug its extremely broad antiviral spectrum.

NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs.

The virus cannot escape NV-387 even as it changes in the field, because the virus continues to use the sulfated proteoglycan features for attachment despite all changes. This is completely unlike existing vaccines, antibodies, and small chemical anti-viral modalities that are all readily defeated by viruses by relatively small changes, often in single viral proteins.

The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.

NV-387 is expected to become an “emperic therapy” for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections.

NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection.

In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.

The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.

NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code-Specific Delivery

Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.

Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.

Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.

ABOUT BIO INTERNATIONAL CONVENTION

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care. From pioneering treatments offering hope to millions, to sustainable agricultural innovations to feed a growing population, or environmental breakthroughs securing our future, biotech drives positive change faster than ever. This progress is not just a change but a promise for a brighter future. The world is ready.

Whether you work at a public pharmaceutical company, biotech startup, academia, non-profit organization, or government agency; or you work as a researcher, business development professional or investor, BIO is where you’ll make valuable connections and build relationships. Our proprietary BIO Partnering™ match-making platform-exclusive to the Premier Access registration package-allows you to find potential partners, schedule and accept meetings.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

NORTH PALM BEACH, FL / ACCESS Newswire / May 27, 2025 / The world of offshore sport fishing is a very close-knit community, and there are very few names that stir the sea quite like Taylor Jean. This Viking Convertible, which is 62 feet in length, is a unique and exceptional tournament yacht. It is sleek and powerful, and it is helmed by a crew that lives and breathes the wide sea. It is a story that is unfolding. From the 28th through the 31st of May 2025, it will once again be the center of attention at the 2nd Annual Walker’s Cay Blue Marlin Open, which is widely considered to be one of the most anticipated fishing competitions in the Bahamas.

A Yacht Built for Glory

Whenever Taylor Jean arrives at a marina, it is difficult to avoid staring at her. It is a beast that was built for speed and precision, as evidenced by its sleek lines, towering outriggers, and twin MTU motors that produce 2002 horsepower each. On the other hand, once you climb onboard, you will experience something else: a sense of purpose. Rather than being only a machine for sport fishing, this vessel serves as a floating home for a group of people who have become like family.

The current Taylor Jean, which first embarked in 2022, was designed with a single objective in mind, to strive for greatness. It is capable of performing with elegance and efficiency, whether it is traveling through the waters of the Bahamas at a speed of 36 knots or managing a hot bite on the tournament circuit.

The Crew Behind the Legend

What truly sets Taylor Jean apart isn’t just its speed, its engineering, or its tournament record, it’s the heartbeat of the boat, the people on board. Behind the polished teak, cutting-edge electronics, and twin MTU engines is a crew bound not just by a love for the ocean but by a shared spirit of competition, trust, and grit. Every line cast, every fish fought, every mile cruised, and it’s the crew that brings it to life.

Blaine Birch, a former collegiate lacrosse player with an unmistakable competitive edge, is currently serving as the captain of the crew. In every excursion, Blaine brings his keen instincts and his ability to lead with composure, guiding his group with self-assurance and a sense of togetherness.

Ken Hager, the owner, is also present, and he is not only the one who finances the dream. He is a living example. This crew is more than just a squad because it includes long-time teammates such as Dave McKendrick and Jarrett Birch (yep, Blaine’s brother). There’s a rhythm to this crew, one built on years of early mornings, high-stakes moments, and the kind of trust you can only earn at sea. They’ve celebrated wins, pushed through quiet days, and built a friendship that runs deeper than most tides. And tucked into their routine is a little superstition that’s become a legend among those who know them, before every tournament, someone scatters a handful of Lucky Charms into the water. No speeches. No ceremony. Just a quiet nod to tradition, a ritual that feels half superstition, half inside joke, and all heart. Maybe it’s luck. Perhaps it’s just who they are. Either way, it’s worked pretty well so far.

A Track Record That Speaks for Itself

Taylor Jean has been in the winner’s circle for quite some time. They finished in third place at the White Marlin Open in 2023, earning a total of 665 points. This is an impressive accomplishment in an event where the competition is just as fierce as the fish themselves. They then followed that up with an equally impressive performance in 2024, which resulted in them matching for third place in the Billfish release division with 770 points.

The yacht has also built a curious streak-claiming top finishes at The MidAtlantic every odd-numbered year since 2017. That kind of consistency speaks to more than just skill. It speaks to tenacity, preparation, and a team that knows how to rise when the stakes are highest.

What’s Coming: The 2025 Walker’s Cay Blue Marlin Open

Now, all eyes are on Walker’s Cay, which has been meticulously renovated and redesigned to become a crown jewel in the Bahamas. In addition to being famous for its deep-water drop-offs and legendary fishing, Walker’s is the ideal location for a Sportfishing Tournament that combines the excitement of competition with the sophistication of the past.

This is not your typical dockside competition, the Walker’s Cay SFC Blue Marlin Open is unlike any other. This event celebrates sport as much as it honors tradition, featuring a full sit-down Captain’s Dinner, an air-conditioned Awards Banquet, and spectacular ocean views.

Taylor Jean’s staff is already getting ready for the event, which includes adjusting the equipment, reviewing the charts, watching films from previous events, and, of course, making sure that the cereal boxes are stocked.

From High Stakes to High Seas: Charter Services with Taylor Jean

However, Taylor Jean is not only a dominant force in tournaments. In addition to that, it provides memorable charter fishing experiences for anyone interested in experiencing life at sea. It doesn’t matter if you’re looking for a day trip to go tuna fishing, a weekend vacation to go sailfish fishing, or just a chance to unplug with your loved ones and friends in opulent surroundings, the Taylor Jean experience will not disappoint.

By putting themselves in the same shoes that champion anglers have worn, guests are accompanied by seasoned anglers, supplied with the best equipment available, and cruise onboard one of the most luxurious yachts in its category. Every charter is customized to the guest’s level of experience if you are a dedicated offshore junkie or a first-timer to the underwater world.

The Legacy Continues

So, what is it about Taylor Jean that sets her apart? It may be the connection that exists between the members of the crew. It is the unwavering concentration. There is a possibility that it is the ideal combination of meticulous engineering and unbridled determination. It could be all of that and much more than that.

There is one thing that can be said with absolute certainty: on May 28th, Taylor Jean will once again be in its element, slashing through the blue of the Bahamas and running after another opportunity to make history.

Are they going to be successful in securing the big one at Walker’s Cay this year? If previous competitions are any indication, keep a close eye on this boat and consider bringing a box of Lucky Charms with you.

To reserve your own adventure, visit https://www.taylorjeanfishing.com/

To follow along on the road to Walker’s Cay, check out their Instagram: @taylorjean_sportfishing and @seabirdsac.

You can also catch full coverage and updates on the tournament at sportfishingchampionship.com, as well as through media like the Miami Herald, which regularly spotlights standout moments from the world of competitive sportfishing.

City, State: North Palm Beach, Florida
Name: Kenneth Hager
Company Name: Taylor Jean FL, LLC
Email Address: ken@taylorjeanfishing.com
Contact Number: (908) 433-6487
Website: taylorjeanfishing.com

SOURCE: Taylor Jean FL, LLC

View the original press release on ACCESS Newswire

Founded by trading educator Jordan Fogel, the platform offers AI-powered options strategies with built-in risk management and hands-off execution

MIAMI, FL / ACCESS Newswire / May 27, 2025 / Cashflow AI (https://trycashflowai.com), a financial technology company specializing in automated options trading, has officially launched its hands-free platform designed to help investors generate consistent passive income through artificial intelligence. The platform provides a modern, accessible solution for capital growth through fully autonomous trading logic-without requiring users to manually execute trades or understand technical charts.

Built for professionals, retirees, and high-net-worth individuals, Cashflow AI connects directly to a user’s U.S.-regulated brokerage account and executes trades based on proven, logic-driven strategies. The platform is compatible with trusted brokers such as Tradier, Charles Schwab, and TastyTrade, allowing users to maintain full control of their capital in their own accounts while the automation operates securely in the background.

The company was founded by veteran trader Jordan Fogel, who previously built Freedom Team Trading, a successful trading education company that supported over 1,000 students and helped generate millions in reported profits. After years of working with individual traders, Fogel saw the need for a simpler, scalable way to participate in the markets-one that eliminates emotional decision-making, missed entries, and over complication.

“Cashflow AI is designed for people who want their money working for them without micromanaging trades,” said a company representative. “We’re focused on stability, transparency, and long-term performance-not hype or speculation.”

How it works:

1. Connect a U.S.-regulated brokerage account

2. Activate the Cashflow AI trading bot

3. Monitor trades and income via a real-time dashboard

All trading is handled automatically using proprietary logic developed by a team with experience in over $500 million of trading volume. The platform’s AI Guardrail™ halts trades during periods of unusual volatility, and the AutoHedge™ system enters both bullish and bearish positions to reduce risk and improve consistency in range-bound or uncertain markets.

Unlike many competitors offering Forex bots or crypto-based systems, Cashflow AI does not use martingale strategies or high-risk compounding models that can jeopardize account balances during drawdowns. Every strategy is rules-based, transparent, and backed by real-world testing in regulated U.S. markets.

Case Study: 15.1% Gain During 2025 Market Crash

Earlier this year, Cashflow AI put its system to the test by deploying a new $50,000 account during what many investors referred to as a market crash. Over the span of 90 days-amid high volatility, uncertainty, and sharp market drops-the account returned a 15.1% gain, fully automated and without any manual trades. The results were documented publicly on the company’s YouTube channel to demonstrate the platform’s real-time decision-making, resilience, and hands-free execution.

This performance was made possible by Cashflow AI’s core risk management features, including its AI Guardrail™ and AutoHedge™ logic. The results highlight how the system adapts to market conditions intelligently-protecting capital while continuing to seek profit opportunities.

With rising demand for passive income and smart investing, Cashflow AI offers a robust alternative to traditional trading or speculative platforms. Its focus on safety, autonomy, and real-world performance makes it an attractive option for those looking to generate income with confidence.

To learn more, visit https://trycashflowai.com.

---

Media Contact:
Cashflow AI LLC
Email: jordan@getcashflowai.com
Website: https://trycashflowai.com

SOURCE: Cashflow AI

View the original press release on ACCESS Newswire

With tech visionaries like Chris Urmson, Clay Bavor, and Dorothy Kilroy, Elevate 2025 promises bold ideas, startup deal flow, and a look at what’s next.

TORONTO, ON / ACCESS Newswire / May 27, 2025 / Canada’s largest made-in-Canada tech and innovation event, Elevate Festival, returns October 7-9 for its seventh annual event at downtown Toronto’s Meridian Hall and St. Lawrence Centre. Organized by Elevate, the non-profit organization that acquired CIX Summit in 2024, Elevate Festival expects 10,000 attendees from across the global tech community, featuring over 250 speakers across eight specialized content tracks.

The festival continues to lead the industry in gender diversity, with 51% of attendees identifying as women or non-binary – significantly exceeding typical tech event benchmarks. Last year’s Elevate Festival catalyzed hundreds of thousands of dollars in direct startup investments, with this year’s event positioned to deliver a similar economic impact for Canada’s innovation ecosystem.

World-Class AI Leaders Takes Center Stage
Following an extraordinary legacy of transformative speakers including former First Lady Michelle Obama, former Google CEO Eric Schmidt, and award-winning tech journalist Kara Swisher, the 2025 lineup delivers world-class inspiration with applied AI as the defining theme. As the industry reflects on lessons learned from AI’s unprecedented acceleration over the past 18 months, this year’s speakers offer critical insights on navigating the next phase of tech transformation responsibly. Featured speakers include:

• Clay Bavor, Co-Founder of Sierra: He co-founded Sierra with former Salesforce co-CEO Bret Taylor to revolutionize customer experience through AI agents, and raised $285 million to serve major brands like WeightWatchers and SiriusXM.

• Chris Urmson, Co-Founder and CEO of Aurora: A Canadian pioneer in self-driving tech. He led Google’s autonomous vehicle project and now oversees driverless freight operations in Texas with Aurora, pushing the boundaries of commercial autonomous trucking.

• Dorothy Kilroy, Chief Commercial Officer at OURAHealth: Former Airbnb executive who led 4M+ hosts globally, creating $180B in earnings. At OURA, she drives partnerships for the $2.55 billion wearables company with major brands including Best Buy, Gucci, and Strava.

• Erika Ayers Badan, CEO of Food52 and former CEO of Barstool Sports: She grew Barstool Sports valuation from $15 million to $450 million. She’s now turning Food52’s culinary family of brands (including Schoolhouse and Dansk) into a cutting-edge content and commerce machine. She is the author of “Nobody Cares About Your Career: Why Failure Is Good, the Great Ones Play Hurt, and Other Hard Truths.”

• Ida Tin, Co-Founder and former CEO of Clue and Director of Femtech Assembly: The visionary who coined “femtech” in 2016 and built Clue into a global phenomenon with 12+ million users across 190+ countries.

• Althea Wishloff, General Partner at Raven Capital: A member of the Gitxsan Nation who leads the only venture fund dedicated to funding Indigenous and Native American entrepreneurs, overseeing a $110 million fund.

• Harley Finkelstein, President of Shopify: Canadian entrepreneur and former CBC Next Gen Dragon, recognized for his leadership and prestigious accolades: Canadian Angel Investor of the Year, Canada’s Top 40 Under 40, and Fortune’s 40 Under 40 awards.

• Hussein Fazal, Co-Founder and CEO of Super.com: Repeat tech entrepreneur who drove $1B in sales on Super.com. His previous accolades include bootstrapping AdParlor to $100M, and receiving EY’s Entrepreneur of the Year recognition.

Additional speakers to be announced.

We’re living through one of the most transformative periods in tech history,” commented Lisa Zarzeczny, Co-Founder & CEO of Elevate. “It’s an honour to welcome leaders who are not just navigating this change, but shaping the future at its very edge.”

Enhanced Programming and Multi-Dimensional Experience
New this year, Elevate’s most popular content tracks, AI and Scale Up, are moving to the Main Stage, enabling over 2,000 people to join each session. The Festival’s eight content tracks address topics most critical to Canada’s innovators: AI, Moonshots, Fintech, Shop Talk, Future Focus, Scale Up, plus specialized programming for investors and Women+ in tech.

Elevate Festival offers multiple specialized experiences all under one roof:

• Gender Parity in Action: The Women in Tech Lounge, presented by Interac, welcomes women+ and invites allies to listen, learn, and take action. It’s a space to show support and become true champions for gender equity in tech.

• Founder Acceleration Hub: The Startup Lounge, presented by Moneris, functions as a compressed accelerator experience, combining 1-1 investor meetings, expert advisory sessions, and high-stakes pitching.

• Deal-Making Infrastructure for Investors: Purpose-built spaces facilitate startup connections, with dealflow sessions that have historically generated funding conversations and commitments.

• Skills-First Learning: Back by popular demand, Masterclasses cap enrollment at 100 to ensure hands-on application, covering immediately implementable strategies from AI deployment to capital acquisition.

• Strategic VIP Networking: The limited-number of premium Trailblazer Passes creates a premium tier where executives forge industry-reshaping partnerships, with dedicated lounges and speaker access.

Beyond the Festival, Elevate runs year-round innovation programs like the eCommerce North Accelerator, made possible thanks to Moneris. These initiatives are woven into the Elevate Festival experience to offer deeper, ongoing support for startups.

Tickets are available now with Early Bird Sale pricing until June 30th. For more information, visit www.ElevateFestival.ca.

Elevate Festival is made possible by its Founding Sponsors: Interac, Moneris and TD Bank Group, as well as its Corporate Sponsors: Google, the Government of Ontario, the City of Toronto, DMZ, Capital One, KPMG, Danone, CPA Ontario, Riipen, OddBee, Bizzabo, Divine Furniture Rental, Get Wrapped, Interprefy, AccessWire and Fintechs Canada, and Official Media Partner: Globe and Mail.

About Elevate
Elevate is a Canadian non-profit that unites world-class innovators to catalyze transformation in the Canadian tech ecosystem. Through year-round programs and events, including the annual Elevate Festival and CIX Summit, Elevate shines a spotlight on Canadian innovation, facilitates global connections with startups and investors, and inspires Canadians to embrace a go-for-gold mentality to help shape the future of the Canadian innovation economy.

—

Media Details:

• Access the Elevate Festival promo video at https://www.youtube.com/watch?v=4mBHZ8K9ysE.

• Photo caption: Kara Swisher and Lisa LaFlamme on stage at Elevate Festival 2024. Photo courtesy of Elevate Festival

• Media can apply for accreditation at Elevatefestival.ca/press-room/. Join the conversation by following @ElevateTechCA and #ElevateFest2025.

Media Contact:
Amanda Connon-Unda
Senior Director of Marketing, Elevate
amanda@elevate.ca

SOURCE: Elevate

View the original press release on ACCESS Newswire

TORONTO, ONTARIO / ACCESS Newswire / May 27, 2025 / Electrovaya Inc. (Nasdaq:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, today announced that it will host an investor webcast presentation on June 3, 2025 at 2:00 PM EDT.

During the webcast, Dr. Raj DasGupta., CEO and John Gibson, CFO, will conduct an introductory presentation that will cover key aspects of Electrovaya’s business including corporate strategy, business model, and industry-leading technology. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

https://us02web.zoom.us/webinar/register/WN_QU4ncWdfRaWS5hVR_-ptkg

Investor and Media Contact:

Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
jroy@electrovaya.com / 905-855-4618

About Electrovaya Inc.

Electrovaya Inc. (NASDAQ:ELVA) (TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries and battery systems for energy storage and heavy duty electric vehicles based on its Infinity Battery Technology Platform. This technology offers enhanced safety and industry leading battery longevity. The Company is also developing next generation solid state battery technology at its Labs division. Headquartered in Ontario, Canada, Electrovaya has two operating sites in Canada and has acquired a 52-acre site with a 135,000 square foot manufacturing facility in New York state for its planned gigafactory. To learn more about Electrovaya, please explore www.electrovaya.com.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

Ambience’s latest AI model reduces coding errors and targets $266 billion in annual administrative waste

SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2025 / Ambience Healthcare today announced a major advancement in ambient AI, unveiling the first AI model that outperforms board-certified physicians in ICD-10 coding accuracy.

Trained using OpenAI’s Reinforcement Fine-Tuning (RFT) technology, Ambience’s AI platform achieved a 27% relative improvement over physician benchmarks-reducing coding errors by approximately one-quarter and offering a powerful tool to tackle the $266 billion in annual administrative waste, including $19 billion in diagnosis coding & documentation substantiation errors.

This new model identifies precise ICD-10 codes based on patient encounters, which feed into Ambience’s ‘coding-aware’ scribe. By leveraging these codes first, the scribe generates a fully informed note-allowing clinicians to review and confirm accurate documentation and coding in real time.

“Think of this technology as a scribe that fluently speaks both clinical language and the intricate healthcare billing rulebook from day one,” said William H. Morris, MD, MBA, Chief Medical Officer of Ambience Healthcare. “Our platform helps clinicians finish their notes faster and ensures that revenue cycle teams receive cleaner, more accurate, and audit-ready charts.”

Ambience is live across inpatient, outpatient, and emergency settings at health systems throughout the United States, supporting over 100 medical specialties with real-time, compliant documentation. Clinicians at more than 40 organizations including UCSF Health, St. Luke’s Health System, Houston Methodist, John Muir Health, and Memorial Hermann Health System leverage Ambience before, during, and after patient encounters to generate compliant documentation, alleviate burnout, and enhance care quality.

How Ambience’s “Coding-Aware” AI Scribe Works
Ambience Healthcare’s platform streamlines the clinical documentation and coding process:

• Clinicians simply tap ‘Record’ on their device, conduct patient visits as usual, and then review a draft note, complete with suggested ICD-10 and CPT codes;

• Ambience integrates natively with major EHRs-including Epic, Oracle Cerner, and athenahealth-ensuring that after clinicians review and sign off, the complete and coded documentation is automatically filed back into the patient’s record;

• By addressing coding at the point of care, Ambience eliminates downstream compliance issues and the time-consuming back-and-forth queries between clinicians and coding/billing departments.

“We built for compliance at the core of our platform because health systems need assurance that AI technology in the workflow can stand up to audits, protect reimbursement, and support clinical documentation integrity,” said Michael Ng, CEO and Co-Founder of Ambience Healthcare. “The stakes of getting this wrong are too high for compliance to be an afterthought.”

Validated Results with RFT Technology
To validate its AI’s mastery of the “coding rulebook,” Ambience assembled a “gold-panel” test dataset of complex clinical cases spanning multiple medical specialties. Each encounter was meticulously labeled by a consensus of four or more expert clinicians to establish a high-quality ground truth.

“Reinforcement Fine-Tuning lets developers align powerful AI models with the precision and robustness that high-stakes domains like healthcare demand,” said Shyamal Anadkat, Head of Startup Solutions at OpenAI. “Ambience’s results show how RFT can lift the performance of AI systems in safety-critical environments”.

The Ambience model was benchmarked against 18 experienced, board-certified physicians on ICD-10 coding accuracy. The results were significant: Ambience’s AI demonstrated a 27% relative improvement in coding performance compared to the expert physician baseline, suggesting the model could help eliminate up to one quarter of the coding errors even the most seasoned clinicians make.

About Ambience Healthcare
Ambience Healthcare is the leading AI platform for clinical documentation, CDI, and coding-built to ensure compliance, eliminate administrative burden, and improve care delivery. Trusted by top health systems across North America, Ambience’s platform is live across outpatient, emergency, and inpatient settings, supporting more than 100 specialties with real-time, coding-aware documentation. The platform integrates directly with Epic, Oracle Cerner, athenahealth, and other major EHRs. Founded in 2020 by Mike Ng and Nikhil Buduma, Ambience is headquartered in San Francisco and backed by Andreessen Horowitz, OpenAI Startup Fund, Kleiner Perkins, and other leading investors.

Media Contact
Karina Stabile
Aria Marketing for Ambience Healthcare
kstabile@ariamarketing.com
516-317-5835

SOURCE: Ambience

View the original press release on ACCESS Newswire